Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- progression-free survival
研究概览
简要总结
The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
详细描述
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with sq-NSCLC;
- •Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
- •≥ 18 years and ≤ 80 years old;
- •No previous treatment in the lungs or any other organ.
排除标准
- •History of cancer treatment;
- •History of other malignant tumors;
- •Irregular treatment or poor compliance;
- •Incomplete clinical information or lost to follow-up.
结局指标
主要结局
progression-free survival
时间窗: A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)
The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
次要结局
- Overall survival(A three-year period after starting treatment (Regular follow-up every six months after receiving immunotherapy combined with or without chemotherapy as first-line treatment))
研究者
Yang Jin
deputy dean
Wuhan Union Hospital, China